Earnings Releases·Nov 5, 2026, 4:13 PM ET

SkinHealth Systems — Third Quarter 2026 Earnings Summary

Q3 2026 total net sales declined 2.1% year-over-year to $69.2 million, driven by a drop in delivery systems, though consumables sales rose to $50.4 million; net loss narrowed significantly to $0.9 million from $11.0 million in Q3 2025, while Adjusted EBITDA increased to $13.4 million.
Full-year 2026 guidance was updated to net sales of $281–$287 million and Adjusted EBITDA of $48–$50 million, reflecting continued sales pressure and ongoing cost discipline.
The company retired $103.2 million in 2026 Notes on September 30, 2026, reducing total liabilities to $333.3 million, while cash and equivalents decreased to $112.4 million from $232.7 million at year-end 2025.
Strategic initiatives included the launch of SkinStylus™ in six European markets and the introduction of the HydraClear™ Treatment Booster, alongside a transition to distributor models in Australia/New Zealand and China.
A 1-for-20 reverse stock split was effected on October 14, 2026, to maintain Nasdaq listing compliance, with management citing improved revenue trends and a healthy adjusted EBITDA margin as indicators of progress.